These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 3346839)
1. Characterization of muscarinic cholinergic receptor subtypes in human peripheral lung. Bloom JW; Halonen M; Yamamura HI J Pharmacol Exp Ther; 1988 Feb; 244(2):625-32. PubMed ID: 3346839 [TBL] [Abstract][Full Text] [Related]
2. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung. Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397 [TBL] [Abstract][Full Text] [Related]
3. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes. Watson M; Roeske WR; Yamamura HI J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581 [TBL] [Abstract][Full Text] [Related]
4. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes. Watson M; Yamamura HI; Roeske WR J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580 [TBL] [Abstract][Full Text] [Related]
5. Solubilization with digitonin alters the kinetics of pirenzepine binding to muscarinic receptors from rat forebrain and heart. Wang JX; Mei L; Yamamura HI; Roeske WR J Pharmacol Exp Ther; 1987 Sep; 242(3):981-90. PubMed ID: 3116203 [TBL] [Abstract][Full Text] [Related]
6. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert. Gil DW; Wolfe BB J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794 [TBL] [Abstract][Full Text] [Related]
7. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain. Luthin GR; Wolfe BB J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265 [TBL] [Abstract][Full Text] [Related]
8. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. Luthin GR; Wolfe BB J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770 [TBL] [Abstract][Full Text] [Related]
9. Characterization of muscarinic receptor subtypes on human peripheral lung. Casale TB; Ecklund P J Appl Physiol (1985); 1988 Aug; 65(2):594-600. PubMed ID: 3170410 [TBL] [Abstract][Full Text] [Related]
10. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization. Luthin GR; Wolfe BB Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291 [TBL] [Abstract][Full Text] [Related]
11. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart. Evans RA; Watson M; Yamamura HI; Roeske WR J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic characterization and functional role of muscarinic autoreceptors in the rabbit striatum. James MK; Cubeddu LX J Pharmacol Exp Ther; 1987 Jan; 240(1):203-15. PubMed ID: 3806384 [TBL] [Abstract][Full Text] [Related]
13. Antagonists and agonists interactions with the muscarinic receptor of the rat large airways. Scott T; McMahon KK J Pharmacol Exp Ther; 1988 Oct; 247(1):136-42. PubMed ID: 3171971 [TBL] [Abstract][Full Text] [Related]
14. Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart. Luthin GR; Harkness J; Artymyshyn RP; Wolfe BB Mol Pharmacol; 1988 Sep; 34(3):327-33. PubMed ID: 3419425 [TBL] [Abstract][Full Text] [Related]
15. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors. Nilvebrant L Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 1():1-45. PubMed ID: 3524114 [TBL] [Abstract][Full Text] [Related]
16. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes. Burke RE Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217 [TBL] [Abstract][Full Text] [Related]
17. Species difference in the muscarinic receptors of thoracic aorta. Yamanaka K; Hashimoto S; Muramatsu I J Pharmacol Exp Ther; 1986 Jun; 237(3):980-6. PubMed ID: 3754896 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates. Lee JH; el-Fakahany EE J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264 [TBL] [Abstract][Full Text] [Related]
19. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Watson M; Yamamura HI; Roeske WR Life Sci; 1983 Jun; 32(26):3001-11. PubMed ID: 6688111 [TBL] [Abstract][Full Text] [Related]
20. High affinity binding of [3H]acetylcholine to muscarinic receptors. Regional distribution and modulation by guanine nucleotides. Gurwitz D; Kloog Y; Sokolovsky M Mol Pharmacol; 1985 Sep; 28(3):297-305. PubMed ID: 4033630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]